@techreport{oai:mie-u.repo.nii.ac.jp:00014530,
 author = {俵, 功 and Tawara, Isao and 池田, 裕明 and Ikeda, Hiroaki},
 month = {May},
 note = {本研究ではマウスを用いて、主要組織適合複合体(MHC)一致および不一致同種造血細胞移植後腫瘍再発モデルを作製し、腫瘍特異的ドナー由来リンパ球輸送(DLI) を、移植2週間後あるいは8週間後に実施した。腫瘍特異的DLIによりすべての条件で抗腫瘍効果が確認され、移植2週間後のDLIでは両モデルにおいて移植片対宿主病(GVHD)の増悪ウが認められた。また移植8週間後のDLIでは、MHC一致モデルのみGVHDの増悪が認められた。, We generated murine models of tumor relapse after major histocompatibility complex(MHC)-matched or mismatiched allogeneic hematopoietic cell transplantation (HCT) and performed tumor-specific donor lymphocyte infusion (DLI) 2 or 8 weeks after HCT. Anti-tumor effect was observed in each setting and GVHD was aggravated graft-vs-host disease (GVHD) in the animals when we performed tumor-specific DLI 2 weeks after HCT. GVHD aggravation was observed only in the recipients of MHC-matched HCT, not in those of MHC-mismatched HCT when we performed tumor-specific DLI 8 weeks after HCT. Our pre-clinical data suggest that GVHD aggravation caused by tumor-specific DLI is dependent on timing and MHC disparity. This study will contribute to clinical development of tumor-specific DLI for the tumor-relapsed patients after allogeneic HCT., 2017年度～2019年度科学研究費補助金(基盤研究(C))研究成果報告書, 17K09949},
 title = {遺伝子改変同種リンパ球による移植後再発腫瘍治療モデル開発と安全性基盤の確立},
 year = {2020},
 yomi = {タワラ, イサオ and イケダ, ヒロアキ}
}